AKT1 and neoplasm: In the randomized phase II LOTUS trial, addition of the AKT inhibitor ipatasertib to first-line paclitaxel improved PFS over paclitaxel alone in treatment naïve mTNBC patients [7]; the benefit was more pronounced in patients with tumours harbouring alterations in the PI3K/AKT pathway, suggesting a clinically significant role of AKT inhibitors in this specific patient population.